Evidence map›Paper›PMID 40708009›Full record

ArticleBMC research notes2025

Screening for mobile colistin resistance gene-9 (mcr-9) in multidrug resistant uropathogenic Escherichia coli isolated from patients with urinary tract infections.

Divya Lakshmanan, K Vanathy, Catherine Thamayandhi, Sreejith Sreekumaran, E K Radhakrishnan, S Srirangaraj

Abstract read
In one paragraph

Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Divya LakshmananMahatma Gandhi Medical Advanced Research Institute (MGMARI), Sri Balaji Vidyapeeth (Deemed-to-be-University), Pondicherry, 607402, India. divyal@mgmari.sbvu.ac.in.ORCID http://orcid.org/0000-0001-7929-8409
K VanathyDepartment of Microbiology, Mahatma Gandhi Medical College and Research Institute (MGMCRI), Sri Balaji Vidyapeeth (Deemed-to-be- University), Pondicherry, 607402, India.
Catherine ThamayandhiMahatma Gandhi Medical Advanced Research Institute (MGMARI), Sri Balaji Vidyapeeth (Deemed-to-be-University), Pondicherry, 607402, India.
Sreejith SreekumaranKerala Institute for Science, Technology and Innovation, Mahatma Gandhi University Campus, Kottayam, 686560, Kerala, India.
E K RadhakrishnanKerala Institute for Science, Technology and Innovation, Mahatma Gandhi University Campus, Kottayam, 686560, Kerala, India.
S SrirangarajDepartment of Microbiology, Mahatma Gandhi Medical College and Research Institute (MGMCRI), Sri Balaji Vidyapeeth (Deemed-to-be- University), Pondicherry, 607402, India.

Funding

Sri Balaji Vidyapeet (Deemed-to-be-University) SBV/IRC/SEED MONEY/138/2023
6 · The paper itself

Abstract

objectiveColistin and Polymyxin B form the reserve group of antibiotics. Resistance to colistin has been increasing across the world including India, posing treatment challenges to clinicians. Use of colistin as a feed supplement in livestock and aquaculture sectors have contributed to the spread of resistance, underlining the need for surveillance among clinical isolates in hospitals. Recently, presence of 10 variants of plasmid-associated mobile colistin resistance (mcr) genes have contributed to colistin resistance in the Gram-negative Enterobacterales. Of these, the mcr-9 is unique in terms of its inducible character in presence of sub-lethal concentrations of colistin, making it clinically relevant. A recent report of mcr-9 from an environmental isolate from Pondicherry prompted us to probe whether the gene cross-over has occurred to our clinical uropathogenic isolates. In this study, we screened for colistin susceptibility and presence of mcr-9 gene among 88 multidrug resistant clinical isolates of uropathogenic E. coli obtained from urine samples of patients with urinary tract infections attending our tertiary care hospital.

resultsWe found that none of the isolates that we screened were colistin or polymyxin B resistant and mcr-9 gene was absent, indicating that there was no cross-over of mcr-9 resistance from the environment to clinical UPEC strains.

Indexed as

Anti-Bacterial AgentsColistinDrug Resistance, Multiple, BacterialEscherichia coli InfectionsEscherichia coli ProteinsUrinary Tract InfectionsUropathogenic Escherichia coliHumansMicrobial Sensitivity TestsPolymyxin BAnti-Bacterial AgentsColistinEscherichia coli ProteinsPolymyxin BAntimicrobial resistanceColistinEscherichia coliMobile colistin resistance (mcr-9) genePolymyxin BUrinary tract infections

Identifiers

PMID40708009
PMCPMC12291223

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.